Ultragenyx Pharmaceutical Inc.
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
About Ultragenyx Pharmaceutical
Pharmaceutical Preparations, SIC 2834
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company engaged in the identification, acquisition, development, and commercialization of therapeutic products. Its business centers on treatments for serious medical conditions, with commercial products and collaborations that include therapies such as Crysvita, Dojolvi, Mepsevii, and Evkeeza. The organization collaborates with biopharmaceutical partners and institutions to advance research, clinical development, licensing arrangements, and product distribution.
The company operates in North America and engages in commercial, licensing, and development activities across international regions, including Latin America, Europe, the Middle East, and the Asia-Pacific territory. It maintains facilities for research, development, and manufacturing. Ultragenyx Pharmaceutical Inc. is organized under the laws of Delaware and maintains its principal executive offices in Novato, California.
Summary of the business section of Ultragenyx Pharmaceutical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ultragenyx Pharmaceutical Inc.
- Founded
- 2010
- Headquarters
- Novato, CA
- Address
- 60 Leveroni Court 94949
- Phone
- (415) 483-8800
- Website
- www.ultragenyx.com
- Employees
- 1,371, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- RARE
- Exchange
- Nasdaq
- IPO date
- Jan 31, 2014
- Shares outstanding
- 99M, Jul 31, 2026
- Public float
- $3.40B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1515673
- CUSIP
- 90400D108
- ISIN
- US90400D1081
- LEI
- 529900EV44GVDN1DCX77
- EIN
- 27-2546083
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Emil D. Kakkis | President & CEO, Director | 2,694,724 |
| Theodore Alan Huizenga | SVP, Chief Accounting Officer | 67,863 |
| Howard Horn | Chief Financial Officer | 96,295 |
| Karah Herdman Parschauer | EVP and Chief Legal Officer | 92,562 |
| Eric Crombez | EVP and Chief Medical Officer | 111,189 |
| Erik Harris | EVP & Chief Commercial Officer | 118,410 |
| John Richard Pinion | See Remarks | 133,142 |
| Dennis Karl Huang | See Remarks | 147,845 |
| Thomas Richard Kassberg | CBO & EVP | 265,238 |
| Corazon (Corsee) D. Sanders | Director | 21,095 |
| Daniel G. Welch | Director | 40,441 |
| Michael Narachi | Director | 40,441 |
| Deborah Dunsire | Director | 38,566 |
| Amrit Ray | Director | 31,116 |
| Shehnaaz Suliman | Director | 27,951 |
| Matthew K. Fust | Director | 33,696 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Kakkis | $11.41M | -$1.29M | $3.83M | $17 | $120 |
| FY2024 Dr. Kakkis | $13.72M | $8.19M | $4.25M | $30 | $91 |
| FY2023 Dr. Kakkis | $13.08M | $11.29M | $4.52M | $35 | $92 |
| FY2022 Dr. Kakkis | $12.14M | $3.31M | $3.91M | $33 | $89 |
| FY2021 Dr. Kakkis | $9.52M | -$2.15M | $3.31M | $61 | $99 |
| FY2020 Dr. Kakkis | $5.14M | $22.73M | $2.71M | $324 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,371 total employees, of which 916 are in research and development and 455 are in sales, general, and administrative.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 18, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 10, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 7, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 10, 2017 | Tender offer | Third-party tender offer for the company's shares |
| Jan 31, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 24, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |